The international success of GLP-1 agonists for weight loss is overwhelming pharma safety operations as they strive to monitor incoming adverse events, says Daniel O’keeffe of Qinecsa Solutions here in Healthcare Business Today.
Their soaring popularity as a weight-loss aid has overwhelmed the pharma industry, which is seeing unforeseen volumes of new safety work as the products’ success continues to go viral internationally.
